|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Youlden DR, Cramb SM and Baade PD: The
International Epidemiology of Lung Cancer: Geographical
distribution and secular trends. J Thorac Oncol. 3:819–831. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kerr KM: Pulmonary adenocarcinomas:
Classification and reporting. Histopathology. 54:12–27. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
Van Schil PE, et al: International association for the study of
lung cancer/american thoracic society/european respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yoshizawa A, Motoi N, Riely GJ, Sima CS,
Gerald WL, Kris MG, Park BJ, Rusch VW and Travis WD: Impact of
proposed IASLC/ATS/ERS classification of lung adenocarcinoma:
Prognostic subgroups and implications for further revision of
staging based on analysis of 514 stage I cases. Mod Pathol.
24:653–664. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zugazagoitia J, Enguita AB, Nuñez JA,
Iglesias L and Ponce S: The new IASLC/ATS/ERS lung adenocarcinoma
classification from a clinical perspective: Current concepts and
future prospects. J Thorac Dis. 6(Suppl 5): S526–S536.
2014.PubMed/NCBI
|
|
7
|
Hung JJ, Jeng WJ, Chou TY, Hsu WH, Wu KJ,
Huang BS and Wu YC: Prognostic value of the new International
Association for the Study of Lung Cancer/American Thoracic
Society/European Respiratory Society lung adenocarcinoma
classification on death and recurrence in completely resected stage
I lung adenocarcinoma. Ann Surg. 258:1079–1086. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Warth A, Muley T, Meister M, Stenzinger A,
Thomas M, Schirmacher P, Schnabel PA, Budczies J, Hoffmann H and
Weichert W: The novel histologic International Association for the
Study of Lung Cancer/American Thoracic Society/European Respiratory
Society classification system of lung adenocarcinoma is a
stage-independent predictor of survival. J Clin Oncol.
30:1438–1446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Song Z, Zhu H, Guo Z, Wu W, Sun W and
Zhang Y: Prognostic value of the IASLC/ATS/ERS classification in
stage I lung adenocarcinoma patients - based on a hospital study in
China. Eur J Surg Oncol. 39:1262–1268. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Paesmans M, Berghmans T, Dusart M, et al:
European Lung Cancer Working Party, and on behalf of the IASLC Lung
Cancer Staging Project: Primary tumor standardized uptake value
measured on fluorodeoxyglucose positron emission tomography is of
prognostic value for survival in non-small cell lung cancer: Update
of a systematic review and meta-analysis by the European Lung
Cancer Working Party for the International Association for the
Study of Lung Cancer Staging Project. J Thorac Oncol. 5:612–619.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chiu CH, Yeh YC, Lin KH, Wu YC, Lee YC,
Chou TY and Tsai CM: Histological subtypes of lung adenocarcinoma
have differential 18F-fluorodeoxyglucose uptakes on the
positron emission tomography/computed tomography scan. J Thorac
Oncol. 6:1697–1703. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yoshizawa A, Sumiyoshi S, Sonobe M, et al:
Validation of the IASLC/ATS/ERS lung adenocarcinoma classification
for prognosis and association with EGFR and KRAS gene mutations:
Analysis of 440 Japanese patients. J Thorac Oncol. 8:52–61. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yanagawa N, Shiono S, Abiko M, et al: The
correlation of the International Association for the Study of Lung
Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory
Society (ERS) classification with prognosis and EGFR mutation in
lung adenocarcinoma. Ann Thorac Surg. 98:453–458. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Travis WD, Brambilla E, Müller-Hermelink
HK and Harris CC: World Health Organization Classification of
Tumours. Pathology and Genetics of Tumours of the Lung, Pleura,
Thymus and Heart (Lyon). IARC Press. 2004.
|
|
15
|
Sica G, Yoshizawa A, Sima CS, Azzoli CG,
Downey RJ, Rusch VW, Travis WD and Moreira AL: A grading system of
lung adenocarcinomas based on histologic pattern is predictive of
disease recurrence in stage I tumors. Am J Surg Pathol.
34:1155–1162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Edge S, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual (7th). New York,
NY: Springer-Verlag. 253–270. 2010.
|
|
17
|
Shaozhang Z, Ming Z, Haiyan P, Aiping Z,
Qitao Y and Xiangqun S: Comparison of ARMS and direct sequencing
for detection of EGFR mutation and prediction of EGFR-TKI efficacy
between surgery and biopsy tumor tissues in NSCLC patients. Med
Oncol. 31:9262014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rosell R, Moran T, Queralt C, Porta R,
Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M,
et al: Spanish Lung Cancer Group: Screening for epidermal growth
factor receptor mutations in lung cancer. N Engl J Med.
361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et
al: Clinical and biological features associated with epidermal
growth factor receptor gene mutations in lung cancers. J Natl
Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Toyooka S, Matsuo K, Shigematsu H, Kosaka
T, Tokumo M, Yatabe Y, Ichihara S, Inukai M, Suehisa H, Soh J, et
al: The impact of sex and smoking status on the mutational spectrum
of epidermal growth factor receptor gene in non small cell lung
cancer. Clin Cancer Res. 13:5763–5768. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hsiao SH, Lin SE, Chou YT, Wang JL, Chung
CL, Yu MC, Fang CL, Lee HL, Chiang LL, Liu HE and Wu CW:
Histological subtype and smoking status, but not gender, are
associated with epidermal growth factor receptor mutations in
non-small-cell lung cancer. Mol Clin Oncol. 2:252–258.
2014.PubMed/NCBI
|
|
23
|
Shim HS, Lee H, Park EJ and Kim SH:
Histopathologic characteristics of lung adenocarcinomas with
epidermal growth factor receptor mutations in the International
Association for the Study of Lung Cancer/American Thoracic
Society/European Respiratory Society lung adenocarcinoma
classification. Arch Pathol Lab Med. 135:1329–1334. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, Xu
X, Jheon S, Lee CT, Lee JS and Chung JH: High incidence of EGFR
mutations in Korean men smokers with no intratumoral heterogeneity
of lung adenocarcinomas: Correlation with histologic subtypes,
EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol.
7:323–330. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Y, Sun Y, Pan Y, et al: Frequency of
driver mutations in lung adenocarcinoma from female never-smokers
varies with histologic subtypes and age at diagnosis. Clin Cancer
Res. 18:1947–1953. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Russell PA, Barnett SA, Walkiewicz M,
Wainer Z, Conron M, Wright GM, Gooi J, Knight S, Wynne R, Liew D
and John T: Correlation of mutation status and survival with
predominant histologic subtype according to the new IASLC/ATS/ERS
lung adenocarcinoma classification in stage III (N2) patients. J
Thorac Oncol. 8:461–468. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Song Z, Zhu H, Guo Z, Wu W, Sun W and
Zhang Y: Correlation of EGFR mutation and predominant histologic
subtype according to the new lung adenocarcinoma classification in
Chinese patients. Med Oncol. 30:6452013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tsuta K, Kawago M, Inoue E, et al: The
utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes
for disease prognosis and correlation of driver gene alterations.
Lung Cancer. 81:371–376. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Villa C, Cagle PT, Johnson M, et al:
Correlation of EGFR mutation status with predominant histologic
subtype of adenocarcinoma according to the new lung adenocarcinoma
classification of the International Association for the Study of
Lung Cancer/American Thoracic Society/European Respiratory Society.
Arch Pathol Lab Med. 138:1353–1357. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun Y, Yu X, Shi X, Hong W, Zhao J and Shi
L: Correlation of survival and EGFR mutation with predominant
histologic subtype according to the new lung adenocarcinoma
classification in stage IB patients. World J Surg Oncol.
12:1482014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim HJ, Choi EY, Jin HJ and Shin KC:
Relationship between EGFR mutations and clinicopathological
features of lung adenocarcinomas diagnosed via small biopsies.
Anticancer Res. 34:3189–3195. 2014.PubMed/NCBI
|
|
32
|
Tokumo M, Toyooka S, Kiura K, et al: The
relationship between epidermal growth factor receptor mutations and
clinicopathologic features in non-small cell lung cancers. Clin
Cancer Res. 11:1167–1173. 2005.PubMed/NCBI
|
|
33
|
Pham D, Kris MG, Riely GJ, et al: Use of
cigarette-smoking history to estimate the likelihood of mutations
in epidermal growth factor receptor gene exons 19 and 21 in lung
adenocarcinomas. J Clin Oncol. 24:1700–1704. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Otto WR: Lung epithelial stem cells. J
Pathol. 197:527–535. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Okudela K, Suzuki M, Kageyama S, et al:
PIK3CA mutation and amplification in human lung cancer. Pathol Int.
57:664–671. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rekhtman N, Ang DC, Riely GJ, Ladanyi M
and Moreira AL: KRAS mutations are associated with solid growth
pattern and tumor-infiltrating leukocytes in lung adenocarcinoma.
Mod Pathol. 26:1307–1319. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Suzuki M, Shigematsu H, Iizasa T, et al:
Exclusive mutation in epidermal growth factor receptor gene, HER-2,
and KRAS, and synchronous methylation of nonsmall cell lung cancer.
Cancer. 106:2200–2207. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vesselle H, Salskov A, Turcotte E, Wiens
L, Schmidt R, Jordan CD, Vallières E and Wood DE: Relationship
between non-small cell lung cancer FDG uptake at PET, tumor
histology, and Ki-67 proliferation index. J Thorac Oncol.
3:971–978. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kadota K, Colovos C, Suzuki K, Rizk NP,
Dunphy MP, Zabor EC, Sima CS, Yoshizawa A, Travis WD, Rusch VW and
Adusumilli PS: FDG-PET SUVmax combined with IASLC/ATS/ERS
histologic classification improves the prognostic stratification of
patients with stage I lung adenocarcinoma. Ann Surg Oncol.
19:3598–3605. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Higashi K, Ueda Y, Yagishita M, Arisaka Y,
Sakurai A, Oguchi M, Seki H, Nambu Y, Tonami H and Yamamoto I: FDG
PET measurement of the proliferative potential of non-small cell
lung cancer. J Nucl Med. 41:85–92. 2000.PubMed/NCBI
|
|
41
|
Hasegawa M, Sone S, Takashima S, Li F,
Yang ZG, Maruyama Y and Watanabe T: Growth rate of small lung
cancers detected on mass CT screening. Br J Radiol. 73:1252–1259.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
de Geus-Oei LF, van Krieken JH, Aliredjo
RP, Krabbe PF, Frielink C, Verhagen AF, Boerman OC and Oyen WJ:
Biological correlates of FDG uptake in non-small cell lung cancer.
Lung Cancer. 55:79–87. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li M, Sun Y, Liu Y, Han A, Zhao S, Ma L,
Zheng J and Yu J: Relationship between primary lesion FDG uptake
and clinical stage at PET-CT for non-small cell lung cancer
patients: An observation. Lung Cancer. 68:394–397. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Usuda K, Sagawa M, Motono N, Ueno M,
Tanaka M, Machida Y, Matoba M, Taniguchi M, Tonami H, Ueda Y and
Sakuma T: Relationships between EGFR mutation status of lung cancer
and preoperative factors - are they predictive? Asian Pac J Cancer
Prev. 15:657–662. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Na II, Byun BH, Kim KM, Cheon GJ, Choe H,
Koh JS, Lee DY, Ryoo BY, Baek H, Lim SM, et al: 18F-FDG uptake and
EGFR mutations in patients with non-small cell lung cancer: A
single-institution retrospective analysis. Lung Cancer. 67:76–80.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mak RH, Digumarthy SR, Muzikansky A,
Engelman JA, Shepard JA, Choi NC and Sequist LV: Role of
18F-fluorodeoxyglucose positron emission tomography in predicting
epidermal growth factor receptor mutations in non-small cell lung
cancer. Oncologist. 16:319–326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Usuda K, Sagawa M, Aikawa H, Ueno M,
Tanaka M, Machida Y, Zhao XT, Ueda Y, Higashi K and Sakuma T:
Correlation between glucose transporter-1 expression and
18F-fluoro-2-deoxyglucose uptake on positron emission tomography in
lung cancer. Gen Thorac Cardiovasc Surg. 58:405–410. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mamede M, Higashi T, Kitaichi M, Ishizu K,
Ishimori T, Nakamoto Y, Yanagihara K, Li M, Tanaka F, Wada H, et
al: [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions
in cancers and inflammatory lesions of the lung. Neoplasia.
7:369–379. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Nguyen XC, Lee WW, Chung JH, et al: FDG
uptake, glucose transporter type 1, and Ki-67 expressions in
non-small-cell lung cancer: Correlations and prognostic values. Eur
J Radiol. 62:214–219. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yun J, Rago C, Cheong I, et al: Glucose
deprivation contributes to the development of KRAS pathway
mutations in tumor cells. Science. 325:1555–1559. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sasaki H, Shitara M, Yokota K, Hikosaka Y,
Moriyama S, Yano M and Fujii Y: Overexpression of GLUT1 correlates
with Kras mutations in lung carcinomas. Mol Med Rep. 5:599–602.
2012.PubMed/NCBI
|
